

Datasheet

KDR polyclonal antibody

Catalog Number: PAB12647

Regulation Status: For research use only (RUO)

Product Description: Rabbit polyclonal antibody raised against synthetic peptide of KDR.

Immunogen: A synthetic peptide corresponding to extracellular domain of human KDR.

Host: Rabbit

Theoretical MW (kDa): 200, 240

Reactivity: Human, Mouse

Applications: ELISA, IHC-P, IP, WB
(See our web site product page for detailed applications information)

Protocols: See our web site at
<http://www.abnova.com/support/protocols.asp> or product page for detailed protocols

Specificity: This antibody recognizes ~200 and ~240 kDa of human KDR.

Form: Liquid

Recommend Usage: Western Blot (0.1-1 ug/mL)
ELISA (0.01-0.1 ug/mL)
Immunoprecipitation (2-5 ug/mL)
Immunohistochemistry (2-5 ug/mL)
The optimal working dilution should be determined by the end user.

Storage Buffer: In PBS, pH 7.2 (10% Proclin300)

Storage Instruction: Store at 4°C. For long term storage store at -20°C or lower.
Aliquot to avoid repeated freezing and thawing.

Entrez GeneID: 3791

Gene Symbol: KDR

Gene Alias: CD309, FLK1, VEGFR, VEGFR2

Gene Summary: Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin α V β 3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq]

References:

1. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Singh N, Tiem M, Watkins R, Cho YK, Wang Y, Olsen T, Uehara H, Mamalis C, Luo L, Oakey Z, Ambati BK Blood. 2013 May 16;121(20):4242-9. doi: 10.1182/blood-2012-08-453043. Epub 2013 Mar 8.
2. An analysis of protein-protein interactions in cross-talk pathways reveals CRKL as a novel prognostic marker in hepatocellular carcinoma. Liu CH, Chen TC, Chau GY, Jan YH, Chen CH, Hsu CN, Lin KT, Juang YL, Lu PJ, Cheng HC, Chen MH, Chang CF, Ting YS, Kao CY, Hsiao M, Huang CY. Mol Cell Proteomics. 2013 Feb 8. [Epub ahead of print]
3. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSA1 in tumor angiogenesis. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A, Claesson-Welsh L. EMBO J. 2005 Jul 6;24(13):2342-53. Epub 2005 Jun 16.